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Intentional introduction of disease has been rare (3). 
Consequently, the incident identified by Thalassinou and her 
colleagues arouses readers’ interest and inspires speculation.
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To the Editor: Metaanalysis of randomized trials that 
tested different probiotics showed a reduction of ≈50% in 
necrotizing enterocolitis and all-cause deaths in preterm in-
fants (1). Use of probiotics is increasing worldwide (2,3), 
and cases of probiotic sepsis were not reported among 
>5,000 infants in an updated review (1). 
In Norway, a consensus-based protocol recommend-
ing prophylactic probiotic supplementation for preterm in-
fants at highest risk for necrotizing enterocolitis (gestation-
al age <28 weeks, birthweight <1,000 g) was introduced in 
2014. After considering the safety profile, we investigated 
use in preterm infants of a widely used combination of oral 
probiotics (Infloran; Laboratorio Farmacéutico Specialità 
Igienico Terapeutiche, Mede, Italy) that contained 109 Lac-
tobacillus acidophilus (ATCC 4356) and 109 Bifidobacte-
rium longum subspecies infantis (ATCC 15697).
B. longum is a microaerotolerant, anaerobic bacterium 
susceptible to many antimicrobial drugs (Table). This bac-
terium is a rare cause of neonatal infections; until 2015, 
only 2 Bifidobacterium bacteremia cases in premature new-
borns had been reported (4,5).
A total of 290 extremely preterm infants received oral 
probiotics during April 2014–August 2015 in Norway. 
Three patients were given a diagnosis of B. longum bac-
teremia: 2 patients in a neonatal unit in which 17 patients 
were given oral probiotics and 1 patient in a neonatal unit 
in which 31 patients were given oral probiotics (Table).
All 3 infants had respiratory distress syndrome and re-
ceived mechanical ventilation after birth. Enteral feeding 
with human milk was begun on day 1. Oral probiotics (½ 
capsule, 1×/d) were given during the first week of life and 
increased to 1 capsule/day after 4–7 days.
We identified B. longum in blood cultures by using ma-
trix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (Bruker Daltonics, Billerica, MA, USA). 
Whole-genome sequencing (MiSeq, Illumina, San Diego, 
CA, USA) and comparative analysis of nucleotide-level 
variation by using variant cell format in  SAMtools (http://
samtools.sourceforge.net) showed that all 3 blood culture 
isolates and a B. longum strain cultured from an oral probi-
otic capsule were identical.
Patient 1 had sepsis and severe hypotension 8 days af-
ter birth. A blood culture was prepared, and the patient was 
given antimicrobial drugs and vasoactive support. Abdomi-
nal distention, gastric residuals, and feed intolerance de-
veloped the next day, but the patient was cardiorespiratory 
stable. On day 12, abdominal radiographs showed pneu-
moperitoneum. Surgery showed multiple ileal perforations 
and bowel necrosis. Histologic analysis showed classical 
features of necrotizing enterocolitis. The patient received 
an ileostoma and improved after treatment with antimicro-
bial drugs. Blood culture was positive for gram-positive 
rods, which were identified as B. longum. Subsequent clini-
cal course was uneventful.
Patient 2 had apnea, bradycardia, and temperature in-
stability 12 days after birth. A blood culture was prepared, 
and the patient was given antimicrobial drugs. Blood cul-
ture was positive for gram-positive rods, which were iden-
tified as B. longum. Use of oral probiotics was discontin-
ued. The patient recovered rapidly, and subsequent clinical 
course was uneventful.
Patient 3 had sepsis and necrotizing enterocolitis 9 days 
after birth. Ultrasound showed free abdominal fluid. A blood 
culture was prepared, and the patient was given antimicrobi-
al drugs. Surgery showed 2 separate bowel perforations, and 
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the patient received an ileostoma and colostoma. Histologic 
analysis did not show necrosis or inflammation. Enterococ-
cus faecalis grew in the blood culture obtained on day 9. The 
patient had a complicated clinical course and received pro-
longed mechanical ventilation. However, the patient gradu-
ally tolerated full feeds. Use of oral probiotics was continued.
On day 46, the condition of patient 3 suddenly deterio-
rated; hypotension and metabolic acidosis developed, and 
the patient was again given antimicrobial drugs. A blood 
culture was positive for B. longum. Supplementation with 
oral probiotics was discontinued. The patient recovered 
from the infection, but secondary ileus developed. The pa-
tient had a complicated clinical course until discharge.
Recently, 5 other B. longum bacteremia cases among 
5 preterm infants at 26–31 weeks gestation were reported 
(6,7). All 5 infants had received oral probiotics; 3 had se-
vere gastrointestinal complications, similar to patient 1 in 
our report, and 2 patients were moderately compromised, 
similar to patient 2 (6,7).
We do not know whether Bifidobacterium organisms 
in blood culture for patient 1 were a consequence of in-
testinal necrosis and bacterial translocation or the cause of 
necrotizing enterocolitis. Patient 3 probably had a leaky gut 
that predisposed this patient to bacterial translocation. All 
3 patients were extremely premature (23–24 weeks ges-
tation) and had impaired immune systems, which predis-
posed them to infections with bacteria with low virulence. 
A recently published case of Bifidobacterium bacteremia 
in a 2-year old boy with leukemia highlights impaired im-
munity as a risk factor (8).
Only aerobic blood cultures are prepared for neo-
nates. We detected Bifidobacterium bacteremia by using 
2 automated blood culture systems and aerobic bottles. 
However, the sensitivity of these systems for detecting Bi-
fidobacterium bacteremia is unknown. Thus, the incidence 
of Bifidobacterium bacteremia is theoretically underesti-
mated. Matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry improves species detection 
and its use might be 1 reason for the apparently recent 
increase in probiotic-associated bacteremia.
We report that systemic infection with probiotic bactere-
mia might have a severe clinical course in extremely preterm 
infants. Clinical suspicion and appropriate blood culture con-
ditions are essential for proper diagnosis and management.
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Table. Characteristics of 3 extremely preterm infants with Bifidobacterium longum subspecies infantis bacteremia, 2015* 
Characteristic Patient 1 Patient 2 Patient 3 
NICU A B A 
Sex M M F 
Date of onset Apr Jul Sep 
Gestational age, wk 24 23 24 
Birth weight, g 730 500 697 
Mode of delivery Vaginal Vaginal Caesarean section 
Apgar score at 1, 5, and 10 min after birth 4, 5, 5 Unknown, 0, 4 2, 2, 3 
Reason for prematurity Preterm rupture of 
membranes, maternal 
infection 
Sudden preterm rupture of 
membranes, delivery not 
attended by healthcare 
personnel 
Placental abruption 
Age at onset of sepsis, d 8 12 46 
Maximum CRP level, mg/L, <48 h of symptom onset 147 25 242 
Age at discharge, wk 40 41 43 
Weight at discharge, kg 3.3 3.4 3.3 
Bacterial culture medium and conditions BacT/ALERT,† aerobic, 
36C 




Bacterial growth in blood culture, d 2 3 2 
*Patients were given ½ to 1 capsule/day of oral probiotics (Infloran; Laboratorio Farmacéutico Specialità Igienico Terapeutiche, Mede, Italy) that 
contained 109 Lactobacillus acidophilus (ATCC 4356) and 109 B. longum subspecies infantis (ATCC 15697). MICs (mg/L) for antimicrobial drugs tested 
were 0.016 for meropenem, 0.032 for ampicillin, 0.064 for penicillin, 0.064 for piperacillin/tazobactam, 0.250 for cefotaxime, 0.250 for clindamycin, 0.250 
for vancomycin, and 4.000 for ciprofloxacin. All bacterial strains were inherently resistant to aminoglycosides. ATCC, American Type Culture Collection 
(Manassas, VA, USA); CRP, C-reactive protein; NICU, neonatal intensive care unit. 
†bioMérieux (Marcy l’Étoile, France). 
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To the Editor: Methicillin-resistant Staphylococcus 
aureus (MRSA) is a versatile pathogen capable of causing 
a wide variety of human diseases. Increased frequency of 
S. aureus infections imposes a high and increasing burden 
on healthcare resources. In many countries, MRSA infec-
tions in hospitals are common. Data from the National 
Nosocomial Infections Surveillance system suggest that, 
in the United States, incidence of nosocomial MRSA in-
fections is steadily increasing and that these infections ac-
count for >60% of intensive care unit admissions (1,2). S. 
aureus has developed resistance to several antimicrobial 
drugs, including second- and third-line drugs. Only a few 
drugs, such as vancomycin (a glycopeptide), daptomycin (a 
lipopeptide), and linezolid (an oxazolidinone), have been 
approved for the treatment of serious infections caused by 
MRSA. Another drug, tigecycline (a glycylcycline), has 
shown good activity against MRSA strains in vitro (3). The 
epidemiology of MRSA is constantly changing, which re-
sults in variation in its drug-resistance patterns throughout 
regions and countries (4). Therefore, to support clinicians 
in preventing and treating infection, epidemiologic surveil-
lance is essential. We report resistance patterns of S. aureus 
collected over 2 years (December 2013–November 2015) 
from blood samples of patients admitted to 1 hospital in 
Odisha, eastern India.
A total of 47 S. aureus isolates were collected; only 1 
isolate per patient was included in the study. Susceptibility 
of the isolates was tested against antimicrobial agents ac-
cording to the Clinical and Laboratory Standards Institute 
broth microdilution procedure and interpretation criteria 
(http://clsi.org/). MICs for the isolates were confirmed by 
using a Vitek 2 Compact automated system (bioMérieux, 
Marcy l’Étoile, France). S. aureus ATCC 25923 was used 
as a control strain. S. aureus identification was confirmed 
by using a Vitek 2 system, by hemolytic activity on blood 
agar, and by positive catalase activity test results. Clinical 
MRSA isolates were analyzed by using PCR with specific 
primers: mecA (5), cfr (6), and VanA (7).
 Among the 47 S. aureus isolates, 28 (60%) were re-
sistant to oxacillin (MICs 4–64 mg/L) and cefoxitin (MICs 
8–64 mg/L). All MRSA isolates were able to grow in selec-
tive medium containing either aztreonam (75 mg/L) or co-
listin (10 mg/L). Screening of MRSA isolates showed that 
2 isolates were highly resistant to vancomycin (MIC >100 
mg/L) (Figure). Further screening showed that both van-
comycin-resistant isolates were also resistant to linezolid 
(MIC >100 mg/L) (Figure). PCR amplification of both iso-
lates indicated presence of all 3 genetic determinants: mecA 
(methicillin resistance), cfr (linzolid resistance), and VanA 
(vancomycin resistance). Among the 3 isolates that showed 
resistance to tigecycline (MIC >50 mg/L), 1 isolate was sus-
ceptible to vanocmycin and linezolid (Figure). Unlike previ-
ously reported isolates, these 2 MRSA isolates showed resis-
tant phenotypes to linezolid, tigecycline, and vancomycin.
MICs observed in this study were higher than those 
previously reported. Vancomycin-resistant S. aureus has 
been identified in many other countries. Most linezolid-
resistant S. aureus has been isolated from patients in North 
America and Europe (8). The tigecycline-resistant S. au-
reus isolate (MIC >0.5 mg/L) reported from Brazil was also 
susceptible to linezolid, teicoplanin, and vancomycin (9).
This study indicates the emergence of multidrug-resis-
tant S. aureus with co-resistance to methicillin, vancomycin, 
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Figure. Distribution of various resistance types of Staphylococcus 
aureus isolates collected in eastern India, 2013–2015. LRSA, 
linezolid-resistant S. aureus; MRSA, methicillin-resistant S. 
aureus; MSSA, methicillin-sensitive S .aureus; TRSA, tigecycline-
resistant S. aureus; VRSA, vancomycin-resistant S. aureus.
